iSBTcInternational Society for Biological Therapy of Cancer
Copyright 1988-2018, All rights reserved.
References in periodicals archive ?
4 October 2010 - US biopharmaceutical company VentiRx Pharmaceuticals Inc announced on Monday at the International Society for Biological Therapy of Cancer (ISBTC) the successful completion of a Phase I study for VTX-2337, its Toll-Like Receptor 8 (TLR8) agonist for oncology.
Additionally, Dr George Coukos, associate chief of the Division of Gynecologic Oncology and director of the Ovarian Cancer Research Center at the University of Pennsylvania Abramson Cancer Center presented preclinical data combining VTX-2337 with Doxil chemotherapy in a poster also at ISBTC entitled "TLR8 Agonist and Doxil chemotherapy potently activate human antitumour immune response in a human immune system mouse model." The preclinical results indicate the combination of VTX-2337 and Doxil elicits potent immune responses in an ovarian cancer model and that further clinical testing is warranted.